DT
FATE icon

Diversified Trust’s Fate Therapeutics FATE Stock Holding History

Diversified Trust’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,287
Closed -$46K – 871
2023
Q4 		$46K Hold
12,287
– – ﹤0.01% 850
2023
Q3 		$26K Sell
12,287
-11,357
-48% -$37.6K ﹤0.01% 816
2023
Q2 		$113K Buy
23,644
+11,357
+92% +$62.7K ﹤0.01% 792
2023
Q1 		$70K Hold
12,287
– – ﹤0.01% 795
2022
Q4 		$124K Buy
12,287
+615
+5% +$11.6K 0.01% 759
2022
Q3 		$262K Sell
11,672
-386
-3% -$11.2K 0.01% 587
2022
Q2 		$299K Hold
12,058
– – 0.01% 564
2022
Q1 		$467K Hold
12,058
– – 0.02% 483
2021
Q4 		$706K Buy
12,058
+754
+7% +$42.7K 0.02% 347
2021
Q3 		$670K Hold
11,304
– – 0.02% 309
2021
Q2 		$981K Buy
11,304
+5,943
+111% +$479K 0.04% 245
2021
Q1 		$442K Buy
+5,361
New +$514K 0.02% 411

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diversified Trust's FATE Position: Q1 2024 in Review

Diversified Trust sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 12,287 shares — an estimated $46K sold.

Diversified Trust first reported a position in FATE in Q1 2021 and held it in 12 quarters. The position peaked at $981K in Q2 2021. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

  • Diversified Trust reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Diversified Trust sold 12,287 Fate Therapeutics shares in Q1 2024, an estimated $46K.
  • Diversified Trust first reported a position in Fate Therapeutics in Q1 2021 and held it in 12 quarters.
  • Diversified Trust's Fate Therapeutics position peaked at $981K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Diversified Trust's 13F filing for Q1 2024, filed 18 Apr 2024.